Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04725240 · ClinicalTrials.gov registry record · Phase 2
Open-Label Study of Setmelanotide in Hypothalamic Obesity
A Phase 2 study, sponsored by Rhythm Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT04725240 is a Phase 2 study that has completed, run by Rhythm Pharmaceuticals. The registered enrollment target is 18 participants.
The verdict
NCT04725240, a Phase 2 study, has completed, sponsored by Rhythm Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
Open-label, single-arm study designed to evaluate the body weight response to setmelanotide administered subcutaneously (SC) daily in participants with hypothalamic obesity (HO).
Interventions
- DRUG Setmelanotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-06-07 |
| Est. Completion | 2022-06-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04725240
The ClinicalTrials.gov registry entry for NCT04725240 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rhythm Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Setmelanotide is the first listed.
NCT04725240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04725240 about?
NCT04725240 is a clinical study titled "Open-Label Study of Setmelanotide in Hypothalamic Obesity". Open-label, single-arm study designed to evaluate the body weight response to setmelanotide administered subcutaneously (SC) daily in participants with hypothalamic obesity (HO).
What is the current status of trial NCT04725240?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2021-06-07. Estimated completion is 2022-06-28.
What interventions are being tested in trial NCT04725240?
The interventions under investigation include: Setmelanotide (DRUG).
Who is sponsoring clinical trial NCT04725240?
This trial is sponsored by Rhythm Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.